Rocatinlimab exhibits positive results in phase 3 study for atopic dermatitis

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.
Rocatinlimab is an investigational therapy that targets the OX40 receptor, a key driver in systemic and local inflammation in AD. The randomized, placebo-controlled, double-blind phase 3 ROCKET HORIZON study evaluating rocatinlimab achieved its co-primary endpoints.
"We are very pleased to have achieved statistically significant efficacy results over placebo which are consistent for co-primary endpoints and all key

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.
Rocatinlimab is an investigational therapy that targets the OX40 receptor, a key driver in systemic and local inflammation in AD. The randomized, placebo-controlled, double-blind phase 3 ROCKET HORIZON study evaluating rocatinlimab achieved its co-primary endpoints.
«We are very pleased to have achieved statistically significant efficacy results over placebo which are consistent for co-primary endpoints and all key